Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

December 4, 2017December 4, 2017

Prostate Cancer Often Deadly for Urban American Indians and Alaskan Natives, Study Shows

News

The mortality toll of prostate and breast cancer is significantly higher in urban American Indian and Alaskan native populations compared to non-Hispanic whites, a retrospective study shows. The study, “Disparities ... Read more

November 20, 2017November 20, 2017

Whole Milk Increases Risk That Overweight Men’s Prostate Cancer Will Return, Study Finds

News

Drinking a lot of whole milk increases the risk that an overweight man’s prostate cancer will return, a study suggests. The results did not apply to men of normal weight ... Read more

November 16, 2017November 17, 2017

Bone-targeted Nanoparticles Could Improve Chemotherapy’s Delivery to Bone Metastasis

News

Researchers at the University of North Texas Health Science Center are developing a new strategy called bone-targeted nanoparticles to improve the delivery of the chemotherapy drug Jevtana (cabazitaxel) to bone metastasis ... Read more

October 26, 2017

EMA’s CHMP Recommends Zytiga Combo Therapy for Certain Early-stage Prostate Cancer Patients

News

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that the prostate cancer combo therapy Zytiga (abiraterone acetate) plus prednisone/prednisolone in combination with androgen deprivation ... Read more

October 25, 2017October 25, 2017

Parkinson’s May Reduce Prostate Cancer Risk in Non-Asians, Chinese Study Finds

News

Parkinson’s disease patients in Western, non-Asian populations may be at lower risk for prostate cancer, while the risk seems higher among Asian men, according to a meta-analysis study. The research, ... Read more

October 23, 2017

Comorbidities Increase Mortality from Causes Other than Prostate Cancer, Study Reports

News

The presence of one or more additional diseases (comorbidity) does not affect the risk of dying from prostate cancer, regardless of treatment type, a Swedish observational study reports. However, high ... Read more

October 20, 2017October 21, 2017

Trovagene’s PCM-075 Increases Zytiga’s Punch Against Prostate Cancer, Studies Show

News

Trovagene’s enzyme inhibitor PCM-075 increases the punch of the prostate cancer therapy Zytiga (abiraterone), preclinical-trial studies show. PCM-075 is a selective polo-like kinase 1 (PLK1) inhibitor. It inhibits a protein called PLK1, whose levels ... Read more

October 18, 2017

New Low-cost Prostate Cancer Tracer Shows Promise for Early Diagnosis in More Patients

News

A PhD student at King’s College London in England developed a new prostate cancer tracer — called 68Ga-THP-PSMA — that is low-cost, quick, and easy to produce. The tracer, which targets the PSMA ... Read more

September 8, 2017September 8, 2017

Aptevo Regains Rights to Prostate Cancer Therapy APVO414, Whose Results Improve After Delivery Method Tweaked

News

Aptevo Therapeutics has ended its partnership with MorphoSys AG for the development and commercialization of APVO414 as a treatment for metastatic castration resistant prostate cancer, or mCRPC. The termination means the company has ... Read more

August 25, 2017August 25, 2017

Prolia, Osteoporosis Therapies Improve Bone Health in Prostate Cancer Patients, Review Suggests

News

A review of clinical trial results revealed that patients with non-metastatic prostate cancer receiving androgen deprivation therapy (ADT) can benefit from osteoporosis therapies, known as bisphosphonates, and from Prolia (denosumab), ... Read more